Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript

Brian Sullivan: Right. So, we have 11 different patents that have been approved for Geda. We have several that are pending. The active pharmaceutical ingredient patent is-would provide an exclusivity period through December 34. But because Geda is formulated and because the formulation actually is critical to being able to deliver the drug, administer the drug, we think that patent will be very relevant. And that patent would have an expiration date of December 39. And so, we think we’ll have extended exclusive period that would potentially carry for more than 15 years post-launch. That’s our plan.

Alex Nowak: Excellent. I appreciate the update. Thank you.

Brian Sullivan: You’re welcome.

Operator: Thank you. There are no further questions at this time. Please proceed.

Brian Sullivan: Well, we appreciate your attendance to the call, and we look forward to updating you in the future.

Operator: Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect.